Erik Wielechowski
About Erik Wielechowski
Erik Wielechowski is a Scientist II in Product Development at Asklepios BioPharmaceutical, Inc., specializing in AAV clinical trial development and laboratory operations. He holds a Master of Science in Biotechnology from the University of Pennsylvania and has extensive experience in gene therapy research.
Work at Asklepios BioPharmaceutical
Currently, Erik Wielechowski holds the position of Scientist II in Product Development at Asklepios BioPharmaceutical, Inc. (AskBio) since 2021. His role involves leading interdisciplinary special projects focused on AAV clinical trial development. He is responsible for the operational buildout of the Philadelphia lab space and manages the in-house molecular biodistribution core. Additionally, he serves as the site safety officer, ensuring compliance with safety regulations and protocols within the laboratory environment.
Education and Expertise
Erik Wielechowski has a strong educational background in biotechnology and biology. He earned a Master of Science (MS) in Biotechnology from the University of Pennsylvania in 2020. Prior to that, he completed a Bachelor of Science (BS) in Biology at Gwynedd Mercy University in 2011. His academic training supports his expertise in clinical development, FDA compliance, and the development of standard operating procedures (SOPs) and technical assays.
Background in Gene Therapy Program
Before joining Asklepios BioPharmaceutical, Erik Wielechowski worked at the Gene Therapy Program at the University of Pennsylvania. He served as a Research Specialist B from 2014 to 2016, followed by a role as Lead, In Vivo Studies from 2020 to 2021. His experience in this program spanned four years, during which he contributed to various research initiatives and gained significant expertise in gene therapy methodologies.
Previous Experience at WuXi AppTec
Erik Wielechowski began his career as an Associate Laboratory Technician in Quality Analytics at WuXi AppTec from 2012 to 2014. This role provided him with foundational experience in laboratory operations and quality assurance processes, which he later applied in his subsequent positions within the biotechnology and gene therapy fields.